Literature DB >> 11193802

Vulnerability of select neuronal types to Alzheimer's disease.

H Braak1, K Del Tredici, C Schultz, E Braak.   

Abstract

From a morphological perspective, Alzheimer's disease (AD) is primarily a degenerative disorder of the neuronal cytoskeleton involving lipofuscin-laden cortical projection neurons with long, thin, and sparsely myelinated axons. The neocortical primary fields, relatively small in extent but functionally sophisticated, exhibit an early and brief myelination cycle, whereas the much more expansive but relatively simply organized association areas undergo a late and prolonged myelination process. The greater the degree of myelination and the less intense the pigmentation, the more resistant a given projection neuron may be to oxidative stress as well as to the development of AD-related neurofibrillary changes and vice versa. The neurofibrillary pathology commences from those cortical areas that are less completely myelinated and gradually progresses to the most functionally developed cortical fields that display the highest degree of myelination, thereby reflecting a hierarchy in the susceptibility of diverse cortical areas to the evolution of the AD-associated cytoskeletal pathology.

Entities:  

Mesh:

Year:  2000        PMID: 11193802     DOI: 10.1111/j.1749-6632.2000.tb05560.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  48 in total

1.  Linking selective vulnerability to cell death mechanisms in Parkinson's disease.

Authors:  Dennis W Dickson
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Smoking impacts on prefrontal attentional network function in young adult brains.

Authors:  Francesco Musso; Franziska Bettermann; Goran Vucurevic; Peter Stoeter; Andreas Konrad; Georg Winterer
Journal:  Psychopharmacology (Berl)       Date:  2006-08-26       Impact factor: 4.530

3.  Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype.

Authors:  C Conejero-Goldberg; T M Hyde; S Chen; U Dreses-Werringloer; M M Herman; J E Kleinman; P Davies; T E Goldberg
Journal:  Mol Psychiatry       Date:  2010-05-18       Impact factor: 15.992

4.  Modeling regional vulnerability to Alzheimer pathology.

Authors:  Donald R Royall; Raymond F Palmer; Helen Petrovitch; G Webster Ross; Kamal Masaki; Lon R White
Journal:  Neurobiol Aging       Date:  2011-07-30       Impact factor: 4.673

5.  A network diffusion model of disease progression in dementia.

Authors:  Ashish Raj; Amy Kuceyeski; Michael Weiner
Journal:  Neuron       Date:  2012-03-21       Impact factor: 17.173

Review 6.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

7.  Different strategies for auditory word recognition in healthy versus normal aging.

Authors:  C J Aine; J E Bryant; J E Knoefel; J C Adair; B Hart; C H Donahue; R Montaño; R Hayek; C Qualls; D Ranken; J M Stephen
Journal:  Neuroimage       Date:  2009-12-03       Impact factor: 6.556

8.  Pattern of lipofuscin pigmentation in nitrergic and non-nitrergic, neurofilament immunoreactive myenteric neuron types of human small intestine.

Authors:  Axel Brehmer; Barbara Blaser; Gerhard Seitz; Falk Schrödl; Winfried Neuhuber
Journal:  Histochem Cell Biol       Date:  2003-12-09       Impact factor: 4.304

9.  Potential of ezetimibe in memory deficits associated with dementia of Alzheimer's type in mice.

Authors:  Yogita Dalla; Nirmal Singh; Amteshwar Singh Jaggi; Dhandeep Singh; Pooja Ghulati
Journal:  Indian J Pharmacol       Date:  2009-12       Impact factor: 1.200

10.  White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI.

Authors:  Yu Zhang; Norbert Schuff; An-Tao Du; Howard J Rosen; Joel H Kramer; Maria Luisa Gorno-Tempini; Bruce L Miller; Michael W Weiner
Journal:  Brain       Date:  2009-05-12       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.